| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5615957 | The Journal of Heart and Lung Transplantation | 2017 | 27 Pages |
Abstract
Prolonged exposure to CNI immunosuppression medications significantly increases the risk for ESRD among HTx recipients. KAH is a good therapeutic option for HTx recipients with ESRD, with survival benefit comparable to HTx without ESRD.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Avishay MD, Ayelet MD, Richard C. MD, Naveen L. MD, Matthew A. MS, Walter K. PhD, Fernando G. MD, Brooks S. MD, Sudhir S. MD,